Invention Title:

ANTI-CD19 CAR T CELLS FOR TREATING B-CELL MALIGNANCIES AND AUTOIMMUNE DISEASES

Publication number:

US20260306629

Publication date:
Section:

Human necessities

Class:

A61K40/11

Inventors:

Applicant:

Smart overview of the Invention

The patent application discusses a novel approach to treat B cell malignancies and autoimmune diseases using engineered hypoimmune allogenic CD19-directed CAR T cells. These cells are designed to overcome the limitations of current therapies, particularly in relapsed and refractory cases of B cell lymphomas, which include non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). The approach aims to provide an off-the-shelf solution that avoids issues like malignant contamination and T cell dysfunction commonly associated with autologous cell-based therapies.

Background

B cell lymphomas are predominantly non-Hodgkin lymphomas, representing a significant portion of diagnosed cases. Despite advancements in treatment, NHL remains a critical unmet medical need, with high incidence and mortality rates. The existing therapies are often ineffective in advanced stages of the disease, necessitating the development of new therapeutic strategies that can effectively target and treat these malignancies.

Innovative Approach

The proposed method involves administering a composition of engineered hypoimmunogenic T cells to patients. These T cells are modified to reduce the expression of molecules that typically trigger immune rejection, such as major histocompatibility complex (MHC) class I and II molecules, and T-cell receptor (TCR) molecules. The modifications aim to enhance the persistence and efficacy of the allogenic CAR T cells by avoiding detection by the patient's immune system.

Technical Modifications

Key modifications include the inactivation or disruption of alleles associated with MHC and TCR molecules, as well as the introduction of exogenous polynucleotides to increase the expression of CD47, which helps the cells evade immune detection. The engineered T cells express a CD19-specific chimeric antigen receptor, enabling them to specifically target and attack B cell malignancies. This approach leverages genetic engineering techniques to enhance the therapeutic potential of CAR T cells.

Potential Benefits

The hypoimmunogenic CAR T cells offer several advantages, including improved manufacturing consistency, reduced risk of immune rejection, and potentially greater efficacy in treating B cell malignancies. By addressing the limitations of traditional therapies, this approach holds promise for providing a more effective and accessible treatment option for patients with B cell-related disorders. The development of such therapies could significantly impact the treatment landscape for B cell malignancies and autoimmune diseases.